Bingham

Bingham

Julio E. Vega

Partner

Julio Vega concentrates on corporate and securities law, with an emphasis on venture capital transactions, mergers and acquisitions, public offerings such as IPOs, joint ventures, strategic alliances, and licensing transactions. He represents emerging growth companies and established businesses in all areas of technology, including advanced materials, biotechnology, e-commerce, nanotechnology, networking, software and telecommunications.

Julio regularly counsels startups on equity-based compensation matters, equity finance strategy, executive employment arrangements, general business strategy and other general corporate issues. He has also represented venture capital firms in connection with portfolio company investments.

Julio is frequently invited to participate in professional events and speak on numerous topics, including securities laws, mergers and acquisitions, and public and private equity and debt financing.

Julio has worked in the firm’s London office on international financing transactions and is fluent in Spanish.

Experience

Representative Matters

  • Venture Capital Financings — Represented many technology and emerging-growth companies in venture capital financings and in equity financings by corporate partners. Julio also has represented venture capital firms in connection with venture capital investments in portfolio companies.
  • Mergers & Acquisitions — Represented both public companies and private companies in a wide range of merger and acquisition transactions, including tender offers, exchange offers and going-private transactions
  • Public Offerings — Represented technology and emerging-growth companies in initial public offerings and secondary public offerings of equity securities. Julio has also represented issuers in connection with Rule 144A offerings of convertible debt securities.
  • Joint Ventures and Strategic Alliances — Represented biotechnology companies in numerous corporate collaborations and strategic alliances with major pharmaceutical companies and large biotechnology companies. Julio has also represented U.S. technology companies in connection with domestic and international joint ventures.
  • Licensing and Distribution Agreements — Represented biotechnology and other high technology companies in connection with many in-licensing and out-licensing transactions involving high technology products and enabling platform technology. Julio has also represented technology companies in connection with product manufacturing and distribution arrangements.

Representative Clients

  • Accenture
  • Acme Packet
  • ActivBiotics
  • Adesso Systems
  • Amicus Therapeutics
  • Analysts in Media
  • Aprilis
  • ArcPoint Systems
  • Cubist Pharmaceuticals
  • DisruptiveApps, Inc. (iJukebox)
  • Draper Laboratories
  • E-Ink
  • Essential Therapeutics
  • Eyegate Pharmaceuticals
  • GGA Software
  • Gryphon Networks
  • InfiMed Therapeutics
  • Innovative Spinal Technologies Inc.
  • LeukoSite (acquired by Millenium Pharmaceuticals)
  • Massachusetts Eye & Ear Infirmary
  • Microbia
  • NewCyte
  • Novazyme Pharmaceuticals (acquired by Genzyme)
  • Organ Recovery Systems
  • Protometrix
  • RA Capital
  • Radius Health (formerly known as Nuvios Inc.)
  • Rezolve Group Inc.
  • Saturn Capital
  • Sequoia Pharmaceuticals
  • Serono
  • Skyscape
  • St. Michael’s Medical
  • Suntory Pharmaceutical Research Laboratories
  • Synovex Corporation
  • TolerRx
  • VaxInnate
  • VisEn Medical
  • Voice Signal Technology

Events

  • Panelist, How to Start a Successful Biotech With Non-existent Capital, MedChem Partners, Boston (April 24, 2014)
  • Speaker, Start-up Investment Secrets, TiE Boston, Boston (Dec. 5, 2013)
  • Panelist, Term Sheet Fundamentals, National Cleantech Open Webinar (July 10, 2012 and July 23, 2013)
  • Speaker, Mergers, Acquisitions and Strategic Alliances, New England Corporate Counsel Association Seminar, Waltham, Mass. (Feb. 16, 2011)

Memberships

  • American Bar Association
  • Massachusetts Bar Association
  • Boston Bar Association
  • Board of Advisers, Sequoia Pharmaceuticals Inc.

Awards & Honors

  • Chambers USA, America’s Leading Lawyers for Business (2007–2012)
  • Legal 500, Corporate (2012–2014)
  • Best Lawyers, Securities Law (2010–2012, 2015)
  • Best Lawyers, Venture Capital Law (2009–2012, 2014–2015)
  • Best Lawyers, Biotechnology Law (2009–2011) 
  • Super Lawyers, Massachusetts (2004–2011, 2013)
  • Lawdragon 500, Dealmakers in America (2007)
  • Chambers Global, noted for Life Sciences (2007)
  • LMG Life Sciences 2012, “LMG Life Sciences Star” for outstanding transactional work

Legal insight. Business instinct. Global intelligence. ®